Lorri Hinton
Family · Clarion, PANPI 1366054389
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,847 of the $2,065 with a category attached, or 89.4%. It is spread thinly across 29 manufacturers, the largest accounting for just 16.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,123, 5.4 times the $209 reported in 2021.
Across 93 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$348
- Novartis$294
- Merck$267
- Johnson & Johnson$176
- E.r. Squibb & Sons, L.L.C.$106
- Eisai Inc.$74
- plus $800 from 23 others
What the payments were for
- Food & beverage$1,84789%
- Education$21811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 17 | $348 |
| Novartis | 11 | $294 |
| Merck | 12 | $267 |
| Johnson & Johnson | 5 | $176 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Eisai Inc. | 3 | $74 |
| Acrotech Biopharma Inc. | 3 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| ADC Therapeutics America, Inc. | 3 | $57 |
| Exelixis Inc. | 2 | $53 |
| GSK | 2 | $50 |
| Rigel Pharmaceuticals, Inc. | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Lilly USA, LLC | 2 | $44 |
| Stemline Therapeutics Inc. | 2 | $41 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| AstraZeneca | 2 | $35 |
| Deciphera Pharmaceuticals Inc. | 2 | $33 |
| Sanofi | 2 | $33 |
| AVEO Pharmaceuticals, Inc. | 2 | $27 |
| Myovant Sciences Inc. | 1 | $24 |
| Genmab U.S., Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Incyte Corporation | 1 | $18 |
| Geron Corporation | 1 | $17 |
| Karyopharm Therapeutics Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Coherus Oncology, Inc. | 1 | $13 |
How this compares
$2,065 in reported general payments places this provider in the 80th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Anastrozole | 62 | $1,298 |
| Potassium Chloride | 40 | $506 |
| Oxycodone Hcl | 21 | $403 |
| Ondansetron Hcl | 13 | $228 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $188 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $169 |
| Nystatin | 16 | $169 |
| Escitalopram Oxalate | 19 | $97 |
| Lorazepam | 18 | $82 |
Paid to pharmacies, not to this prescriber.
Other family in Clarion
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
- Patricia HabdasPittsburgh$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.